Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QYJD Compound Preparation for Postoperative Recovery in Early-stage NSCLC
NCT06766565Phase 1Completed
- Sponsor
- 900th Hospital of Joint Logistics Support Force of PLA
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- HM (Herbal Medicine), TCM (Traditional Chinese Medicine)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Quyu Jiedu Decoction in non-small cell lung cancer (NSCLC) (2 arms), sponsored by 900th Hospital of Joint Logistics Support Force of PLA. Primary endpoints: Rapid rehabilitation indexes at 15 days and Laboratory indicators of inflammation at 1 year. Started Dec 2021; status: completed.
02
Drugs
Quyu Jiedu Decoction
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06766565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766565.